Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MRK with free AI briefings, catalyst countdowns, and dilution alerts.

MRK · Merck & Co., Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$11.3B Cash on Hand
CF+ Cash Runway
1.1% Short Interest
$161.53 Analyst Target (26)
Follow MRK by email Get an email when MRK reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MRK, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Berahyaluronidase Alfa and Pembrolizumab…
FDA approved Sep 2025 · Keytruda Qlex
Non-small Cell Lung Cancer Phase 3 · NCT07431827 Recruiting
Pembrolizumab
FDA approved Sep 2014 · Keytruda
Carcinoma, Non-Small-Cell Lung Phase 3 · NCT06623422 Recruiting
Sotatercept
FDA approved Mar 2024 · Winrevair
Pulmonary Hypertension Phase 3 · NCT07839585 Not yet recruiting
Belzutifan
FDA approved Aug 2021 · Welireg
Malignant Neoplam Phase 2 · NCT07793942 Recruiting
Fluorouracil Bladder Cancer Phase 3 · NCT07829783 Recruiting
Calderasib (MK-1084) Non-small Cell Lung Cancer Phase 3 · NCT07431827 Recruiting
Doxorubicin Breast Neoplasms Phase 3 · NCT06966700 Recruiting
Resiquimod Sulfate (EIK1001) Non Small Cell Lung Cancer (Squamous or Non Squamous) Phase 2/3 · NCT07365319 Recruiting
Enlicitide Hyperlipidemia Phase 3 · NCT07216482 Completed
Ensifentrine Pulmonary Disease, Chronic Obstructive Phase 3 · NCT07874815 Recruiting
Epirubicin Breast Neoplasms Phase 3 · NCT06966700 Recruiting
H1 receptor antagonist Ovarian Cancer Phase 3 · NCT06824467 Recruiting
Histamine-2 Receptor Antagonist Ovarian Cancer Phase 3 · NCT06824467 Recruiting
Intismeran Autogene Non-small Cell Lung Cancer Phase 3 · NCT07513376 Recruiting
IV Tulisokibart Crohn's Disease Phase 3 · NCT06430801 Recruiting
MMC Bladder Cancer Phase 3 · NCT07829783 Recruiting

Also used in these trials (approved or third-party drugs, not MRK's own candidates): Abiraterone Acetate, Acalabrutinib, Acetaminophen, Bevacizumab, Capecitabine, Carboplatin, Cisplatin, Cladribine, Cyclophosphamide, Dexamethasone, Docetaxel Anhydrous, Enzalutamide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MRK holds $11.3B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MRK files for a raise →

👥 Who Owns MRK

Insiders 0% Institutions (4941 holders) 82.8% Public and other holders 17.2%
HolderTypeShares% of sharesAs of
Blackrock Inc. Institution (13F) 228,073,244 9.25% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 186,323,766 7.56% 2026-03-31
State Street Corporation Institution (13F) 121,422,392 4.93% 2026-09-30
Wellington Management Group, LLP Institution (13F) 71,664,541 2.91% 2026-09-30
Vanguard Portfolio Management LLC Institution (13F) 68,109,899 2.76% 2026-09-30
Geode Capital Management, LLC Institution (13F) 61,565,702 2.50% 2026-09-30
Charles Schwab Investment Management, In Institution (13F) 50,826,533 2.06% 2026-09-30
Morgan Stanley Institution (13F) 48,234,438 1.96% 2026-09-30
FMR, LLC Institution (13F) 46,222,051 1.87% 2026-09-30
JPMORGAN CHASE & CO Institution (13F) 43,115,332 1.75% 2026-09-30
Robert M Davis
Chairman, CEO & President, Director · +187,421 options
Insider 450,351 0.02% 2026-05-05
Richard R. DeLuca
EVP&Pres, Merck Animal Heallth · +46,855 options
Insider 114,291 0.00% 2026-11-12

Share count 2,465,245,688 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-12
filed 2026-11-16
DeLuca Richard R.
Option exercise (M) 58,185 $77.62 171,140
2026-11-12
filed 2026-11-16
DeLuca Richard R.
Sale (S) 58,185 $148.01 112,955
2026-11-12
filed 2026-11-16
DeLuca Richard R.
Option exercise (M) 58,185 – –
2026-11-01
filed 2026-11-03
DIAZ PAUL J
Option award (A) 613 $149.52 –
2026-09-30
filed 2026-10-01
Karsanbhai Surendralal Lanca
Option award (A) 112 $145.31 –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full MRK picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MRK and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.